AU2013277971B2 - Molecular malignancy in melanocytic lesions - Google Patents

Molecular malignancy in melanocytic lesions Download PDF

Info

Publication number
AU2013277971B2
AU2013277971B2 AU2013277971A AU2013277971A AU2013277971B2 AU 2013277971 B2 AU2013277971 B2 AU 2013277971B2 AU 2013277971 A AU2013277971 A AU 2013277971A AU 2013277971 A AU2013277971 A AU 2013277971A AU 2013277971 B2 AU2013277971 B2 AU 2013277971B2
Authority
AU
Australia
Prior art keywords
mir
dna
sample
biomarkers
artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013277971A
Other languages
English (en)
Other versions
AU2013277971A1 (en
Inventor
Justin Brown
Dave S.B. Hoon
B.J. Kerns
Zhenquiang LU
Krishna MADDULA
Christopher Roberts
Bruce Seligmann
Tom VASICEK
Hui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wayne Cancer Institute
HTG Molecular Diagnostics Inc
Original Assignee
John Wayne Cancer Institute
HTG Molecular Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wayne Cancer Institute, HTG Molecular Diagnostics Inc filed Critical John Wayne Cancer Institute
Publication of AU2013277971A1 publication Critical patent/AU2013277971A1/en
Application granted granted Critical
Publication of AU2013277971B2 publication Critical patent/AU2013277971B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013277971A 2012-06-22 2013-06-24 Molecular malignancy in melanocytic lesions Active AU2013277971B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663428P 2012-06-22 2012-06-22
US61/663,428 2012-06-22
PCT/US2013/047354 WO2013192616A1 (en) 2012-06-22 2013-06-24 Molecular malignancy in melanocytic lesions

Publications (2)

Publication Number Publication Date
AU2013277971A1 AU2013277971A1 (en) 2015-01-29
AU2013277971B2 true AU2013277971B2 (en) 2018-11-15

Family

ID=49769469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013277971A Active AU2013277971B2 (en) 2012-06-22 2013-06-24 Molecular malignancy in melanocytic lesions

Country Status (7)

Country Link
US (1) US9758829B2 (https=)
EP (1) EP2864500B1 (https=)
JP (1) JP6366580B2 (https=)
CN (1) CN104603291B (https=)
AU (1) AU2013277971B2 (https=)
CA (1) CA2875710C (https=)
WO (1) WO2013192616A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149629A1 (en) * 2013-03-15 2014-09-25 Htg Molecular Diagnostics, Inc. Subtyping lung cancers
US11021752B2 (en) * 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
WO2014182330A1 (en) 2013-05-06 2014-11-13 Hitachi Chemical Company Ltd Devices and methods for capturing target molecules
JP6496899B2 (ja) * 2014-07-01 2019-04-10 公立大学法人福島県立医科大学 浸潤性髄膜腫判別用試薬、及びその判別方法
EP3164508B1 (en) * 2014-07-02 2023-06-07 Myriad myPath, LLC Genes and gene signatures for diagnosis and treatment of melanoma
EP3218521B1 (en) * 2014-11-12 2019-12-25 Hitachi Chemical Co., Ltd. Method for diagnosing organ injury
WO2016152352A1 (ja) * 2015-03-20 2016-09-29 国立大学法人名古屋大学 メラノーマ特異的バイオマーカー及びその利用
GB2544834A (en) * 2015-06-09 2017-05-31 Waters Technologies Corp Profile diagnositcs in personalized dermatology, dermatopathology and cosmetics
GB2565238A (en) * 2015-06-09 2019-02-06 Waters Technologies Corp Molecular diagnostics in personalized dermatology, dermatopathology and cosmetics
CN107636678B (zh) * 2015-06-29 2021-12-14 北京市商汤科技开发有限公司 用于预测图像样本的属性的方法和设备
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
JP7354099B2 (ja) * 2017-10-03 2023-10-02 ジェネシーク ピーティーワイ リミテッド マイクロｒｎａ遺伝子発現を使用して黒色腫を診断し、病期分類し、モニタリングする方法
US20210012214A1 (en) * 2018-03-29 2021-01-14 Nec Corporation Learning apparatus, learning method, and computer-readable recording medium
CN108537005B (zh) * 2018-04-03 2019-04-02 福州大学 一种基于BPSO-KNN模型的关键lncRNA预测方法
JP7526100B2 (ja) 2018-05-31 2024-07-31 バークレー ライツ，インコーポレイテッド マイクロ流体デバイスによる微小物体の自動検出及び特徴付け
US11017896B2 (en) * 2018-06-28 2021-05-25 Case Western Reserve University Radiomic features of prostate bi-parametric magnetic resonance imaging (BPMRI) associate with decipher score
FR3085825B1 (fr) 2018-09-14 2021-07-16 Fermentalg Huile de microorganismes riche en acide docosahexaenoique
FR3085962B1 (fr) 2018-09-14 2021-06-18 Fermentalg Procede d'extracton d'une huile riche en pufa
TW202018727A (zh) 2018-11-09 2020-05-16 財團法人工業技術研究院 整體式學習預測方法與系統
CN112513891B (zh) * 2019-01-02 2025-12-05 松下电器（美国）知识产权公司 信息处理装置、信息处理方法及记录介质
CN114693646B (zh) * 2022-03-31 2023-04-11 中山大学中山眼科中心 一种基于深度学习的角膜内皮细胞活性因子的分析方法
JP7806660B2 (ja) * 2022-11-11 2026-01-27 コニカミノルタ株式会社 検出方法
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases
CN117625632A (zh) * 2024-01-22 2024-03-01 中国医学科学院北京协和医院 肌萎缩侧索硬化症的SQSTM1的p.L382CfsTer13突变致病基因及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
WO1985001051A1 (en) 1983-09-02 1985-03-14 Molecular Biosystems, Inc. Oligonucleotide polymeric support system
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
EP0758403B1 (en) 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5866330A (en) 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5736330A (en) 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
US6449562B1 (en) 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US20030096232A1 (en) 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US6232066B1 (en) 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
US6238869B1 (en) 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6458533B1 (en) 1997-12-19 2002-10-01 High Throughput Genomics, Inc. High throughput assay system for monitoring ESTs
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
AU2375600A (en) 1998-12-22 2000-07-12 Stephen Felder High throughput assay system using mass spectrometry
WO2000066265A2 (en) 1999-04-27 2000-11-09 Ciphergen Biosystems, Inc. Probes for a gas phase ion spectrometer
EP1410011B1 (en) 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
JP2007527247A (ja) 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
BRPI0512587A (pt) 2004-06-25 2007-09-18 Veridex Llc processo e reagentes para detecção de melanoma
CN101687022B (zh) 2007-03-26 2016-09-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
US20080268451A1 (en) 2007-03-30 2008-10-30 Bruce Seligmann Measurement of an insoluble analyte in a sample
WO2009099905A2 (en) * 2008-02-01 2009-08-13 Memorial Health Inc. Molecular signatures and biomarkers associated with melanoma and methods of use thereof
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2619332A4 (en) 2010-09-22 2014-04-16 Dave S B Hoon DIRECT BLOOD ASSAY TO DETECT MICROARN CIRCULATING IN PATIENTS WITH CANCER
ES2597032T3 (es) 2011-05-04 2017-01-13 HTG Molecular Diagnostics, Inc Mejoras en un ensayo cuantitativo de protección contra la nucleasa (qNPA) y secuenciación (qNPS)
AU2012316129B2 (en) 2011-09-28 2017-10-05 Htg Molecular Diagnostics, Inc. Methods of co-detecting mRNA and small non-coding RNA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
WO2012031008A2 (en) * 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Affymetrix, "Genechip Human Genome Arrays", Affymetrix Datasheet, (2003-08-12) *
FOUNTAIN, J.W. ET AL, "Homozygous deletions within human chromosome band 9p21 in melanoma", PNAS USA, (1992), vol. 89, pages 10557 - 10561 *
Mauerer et al (Exp Dermatol, 2011, 20(6): Abstract). *
Talantov et al (Clinical Cancer Research, 2005, 11(20): 7234-7242). *
TOKITA, T. ET AL., "Methylation status of the SOCS3 gene in human malignant melanomas", INT. J. ONCOLOGY, (2007), vol. 30, pages 689 - 694 *
YU, H. ET AL., "Nuclear Orphan Receptor TR3/Nur77 Mediates Melanoma Cell Apoptosis", CANCER BIOLOGY & THERAPY, (2007), vol. 6, pages 405 -412 *

Also Published As

Publication number Publication date
CN104603291A (zh) 2015-05-06
EP2864500B1 (en) 2018-08-22
CN104603291B (zh) 2018-04-06
WO2013192616A1 (en) 2013-12-27
CA2875710C (en) 2021-06-29
EP2864500A1 (en) 2015-04-29
CA2875710A1 (en) 2013-12-27
US9758829B2 (en) 2017-09-12
JP6366580B2 (ja) 2018-08-01
AU2013277971A1 (en) 2015-01-29
US20150176072A1 (en) 2015-06-25
JP2015521483A (ja) 2015-07-30
EP2864500A4 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
AU2013277971B2 (en) Molecular malignancy in melanocytic lesions
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN109863251B (zh) 对肺鳞状细胞癌亚型分型的方法
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
CN107077536B (zh) 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性
AU2012345789B2 (en) Methods of treating breast cancer with taxane therapy
KR100964193B1 (ko) 간암 예후 마커
KR102921718B1 (ko) 전립선암 검출 및 치료 방법
KR20160052729A (ko) 폐암에 대한 분자적 진단 검사
WO2021183218A1 (en) Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
AU2016331663A1 (en) Pathogen biomarkers and uses therefor
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
US12366575B2 (en) Chemical compositions and methods of use
AU2008203226A1 (en) Colorectal cancer prognostics
US20020137077A1 (en) Genes regulated in activated T cells
AU2004205270B2 (en) Colorectal cancer prognostics
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
CN101111768A (zh) 肺癌预后
US20030175761A1 (en) Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma
KR20110113642A (ko) 유방 종양의 하위분류 방법
CN101827948A (zh) 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记
KR20100115283A (ko) 간암 예후 마커

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)